Filing Details

Accession Number:
0001596783-21-000093
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-07-28 16:27:00
Reporting Period:
2021-07-26
Accepted Time:
2021-07-28 16:27:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1596783 Catalent Inc. CTLT Pharmaceutical Preparations (2834) 208737688
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1612357 Aristippos Gennadios C/O Catalent, Inc.
14 Schoolhouse Road
Somerset NJ 08873
President Softgel & Oral Tech No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-07-26 465 $113.05 50,850 No 4 S Direct
Common Stock Acquisiton 2021-07-26 885 $0.00 51,735 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 A Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Options to purchase Common Stock Acquisiton 2021-07-26 4,579 $0.00 4,579 $113.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,579 2031-07-26 No 4 A Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to cover tax withholding obligations in connection with the vesting of restricted stock received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer.
  2. Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $112.77 to $113.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Includes restricted stock units.
  4. Restricted stock units (RSUs) received by the reporting person pursuant to the Issuer's annual grant to executive officers and other personnel under its long-term incentive plan. Each RSU represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur three (3) years from the date of award.
  5. Received by the reporting person pursuant to the Issuer's annual grant to executive officers and other personnel under its long-term incentive plan.
  6. The options vest and become exercisable in four equal annual installments beginning on July 26, 2022.